Protagenic Therapeutics, Inc. Financials

PTIX

All currency values in $ millions unless otherwise noted

Scroll

Showing 5 of 14 available years

Income Statement	MAR 2026	MAR 2025 ~15.4:1 split	DEC 2024	DEC 2023	DEC 2022
Revenues
Revenue	$0	$0	$0	$0	$0
General & Administrative	$0	$0	$2	$1	$2
Research & Development	$1	$0	$4	$3	$2
Provision for Doubtful Accounts	–	$1	–	–	–
Total Operating Expenses	$5	$3	$6	$5	$4
Operating Income	-$5	-$3	-$6	-$5	-$4
Non-Operating
Net Interest Expense	–	–	$0	$0	$0
Other Non-Operating Income (Expense)	$6	-$1	$0	-$1	-$0
EBT (Earnings Before Tax)	$1	-$4	-$6	-$5	-$4
Net Income
Net Income	$1	-$4	-$6	-$5	-$4
Per Share Data
Revenue Per Share	$0.00	$0.00	$0.00	$0.00	$0.00
EPS (Basic)	$0.59	-$0.67	-$15.82	-$16.10	-$11.48
EPS (Diluted)	$0.59	-$0.67	-$15.82	-$16.10	-$11.48
Weighted Avg Shares (Basic)	2.3M	5.4M	4.9M	4.3M	4.3M
Weighted Avg Shares (Diluted)	2.3M	5.4M	4.9M	4.3M	4.3M
Shares Outstanding	2.3M	5.4M	349,996.643	310,327.143	308,419.643

Protagenic Therapeutics (PTIX) financials: revenue, profit and margins

Protagenic Therapeutics (PTIX) generated about n/a in revenue and $5 million in net income over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.

Frequently asked

Is Protagenic Therapeutics profitable?+

Yes, Protagenic Therapeutics reported about $5 million in net income over the trailing twelve months. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.

More on PTIX: Overview · Quality scorecard · DCF valuation · Dividend safety

How the market compares: How many US companies are profitable

SourceFinancial statements computed from the 10-Q filed 19 Aug 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Fiscal year ends Mar.

Peers

Pharmaceutical Preparations · Pick stocks to compare with PTIX

CompareIntrinsic value

GCANThe Greater Cannabis Company, Inc.

$0.75+0.00%20

BOLTBolt Biotherapeutics Inc.

$6.54-0.46%25

EQEquillium, Inc.

$1.40-0.71%40

ABEOAbeona Therapeutics Inc.

$4.22-0.71%40

JAZZJazz Pharmaceuticals plc

$234.66+2.14%58

CBIOCrescent Biopharma, Inc.

$13.42+2.76%50

AYTUAytu BioPharma Inc.

$1.92-0.52%48

JNJJohnson & Johnson

$276.34+3.82%53

Spot a number that looks wrong? Check it in PTIX's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing PTIX

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.